Extra proxy material
Open the filing on sec.gov
Skye Bioscience, Inc. (SKYE)
Nasdaq: SKYE · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2011
The companyfiscal 2025, as filed
Revenuen/a
Net income-$55.9M-110.5%
Earnings per share$-1.41-93.2%
Operating cash flow-$43.1M-70.6%
Cash$5.9M-91.4%
Debtn/a
Shareholders’ equity$20.0M-70.6%
Shares, diluted39.7M+8.7%
Return on equity-279.3%
The recordfrom its filings
Filings in 202662
Newest filingNov 12 · DEFA14A
Annual reportMar 10, 2026
Quarterly reportAug 14, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$400,000
Insider buys, 12 months$0.00
Patents granted0
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jun 2026Net income -$50.5MCash from operations -$38.8Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Current report
Open the filing on sec.gov
Form PRER14A
Open the filing on sec.gov
Preliminary merger proxy
Open the filing on sec.gov
Large holder notice
Open the filing on sec.gov
Activist holder update, amended
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.